companiesCompany
InnoPharmax
aka InnoPharmax Inc.
InnoPharmax is a Taiwanese pharmaceutical company running phase 3 trials of D07001, its oral formulation of the chemotherapy irinotecan, in biliary tract cancer.
Overview
InnoPharmax, based in Taipei, develops oral formulations of established cancer drugs. Its lead programme D07001 is an oral form of irinotecan designed to allow outpatient dosing, in phase 3 trials for advanced biliary tract cancer after first-line chemotherapy. Sponsor and trial facts are from the ClinicalTrials.gov registry.
Headquarters
Taipei, TW
Scorecard
All companies#227of 782 companies, score 8
- phase 3 +3
- modalities +2
- registry trials +3
0 approved, 1 in phase 3, 0 earlier, 0 targets, 3 registry studies. Formula on the scorecards page.
Type
biotech
Stage
Growth stage
Similar pages
not linked directly; found by shared links- CompanyTiumBio
Shares Biliary tract cancer (cholangiocarcinoma) and the tag ctgov-sponsor.
- CompanyHangzhou Hanx Biopharmaceuticals
Shares Biliary tract cancer (cholangiocarcinoma) and the tag ctgov-sponsor.
- CompanyShenzhen Ionova Life Sciences
Shares Biliary tract cancer (cholangiocarcinoma) and the tag ctgov-sponsor.